SOBI — Swedish Orphan Biovitrum AB (publ) Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Market Cap
SEK95.34bn
Enterprise Value
SEK110.94bn
Revenue
SEK26.03bn

Annual income statement for Swedish Orphan Biovitrum AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	15,261	15,529	18,790	22,123	26,027
Cost of Revenue
Gross Profit	12,036	12,045	14,377	17,171	20,310
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	10,443	11,796	14,977	18,057	20,402
Operating Profit	4,818	3,733	3,813	4,066	5,625
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,217	3,295	3,321	2,954	4,407
Provision for Income Taxes
Net Income After Taxes	3,245	2,679	2,638	2,408	3,879
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,245	2,679	2,638	2,408	3,885
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,245	2,679	2,638	2,409	3,885
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	9.43	8.79	10.2	8.63	11.7
Dividends per Share